Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Antidepressant response to a single subanesthetic dose infusion of the glutamatergic modulator ketamine is transient in most depressed patients; however, a minority continue to experience an extended response. This study examined depressive symptoms and potential clinical predictors of extended response to ketamine in subjects with mood disorders. Methods Subjects were diagnosed with either major depressive disorder (MDD) or bipolar depression. All subjects were treatment-resistant and experiencing a major depressive episode of at least moderate severity. MDD subjects were unmedicated and those with bipolar depression were receiving therapeutic-dose lithium or valproate. All subjects received a single 0.5 mg/kg ketamine infusion. Data were collected pre-infusion (baseline) and at days one, 14, and 28 post-infusion. Results Twelve of 93 (12.9%) participants continued to meet response criteria (50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score) at two weeks. All depressive symptoms assessed by the MADRS were improved at two weeks in ketamine responders except for sleep duration/depth. A positive family history of alcohol use disorder in a first-degree relative (FHP) and greater dissociation during the infusion were associated with better antidepressant response at two weeks. Improved measures of apparent sadness, reported sadness, inability to feel, and difficulty concentrating at day 1 correlated most strongly with antidepressant effects at two weeks. Limitations Post-hoc design, small sample size, diagnostic heterogeneity. Conclusions: Static (FHP) and dynamic (improved depressive symptoms) factors may be clinically useful in predicting whether a patient will have an extended response to ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“…with antidepressant efficacy in longitudinal MDD and bipolar clinical trials but also included variables previously reported to be associated with ketamine’s antidepressant effects (Niciu et al., 2014c; Niciu et al., 2014d; Obrocea et al., 2002; Permoda-Osip et al., 2014; Trivedi et al., 2006).”
BackgroundCross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 4×
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultInfluentialSelf-citationBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Increased slow-wave sleep is considered a biomarker of enhanced synaptic plasticity (Vyazovskiy et al., 2008), which has been implicated in ketamine’s antidepressant mechanism of action (Bjorkholm and Monteggia, 2016; Duncan et al., 2013).”
BackgroundVyazovskiy, V. V., Cirelli, C., Pfister-Genskow, M., Faraguna, U., & Tononi, G. (2008) · Nature Neuroscience · doi:10.1038/nn2035 · Cited by 837 · cited 1×
“Increased slow-wave sleep is considered a biomarker of enhanced synaptic plasticity (Vyazovskiy et al., 2008), which has been implicated in ketamine’s antidepressant mechanism of action (Bjorkholm and Monteggia, 2016; Duncan et al., 2013).”
BackgroundBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 4×
“Pearson correlations were used to examine associations between percent change in MADRS score at two weeks post-ketamine infusion and the following: (1) the raw values of individual symptoms one day after infusion, and (2) baseline demographic and neuropsychiatric variables and total CADSS score at the end of the 40-mi…”
MethodInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 3×
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultSelf-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 7×
“Nevertheless, the most promising antidepressant maintenance strategy currently under investigation appears to be repeated-dose ketamine infusions; yet, to date, only a few such studies have been conducted (aan het Rot et al., 2010; Cusin et al., 2016; Diamond et al., 2014; Murrough et al., 2013; Rasmussen et al., 2013…”
BackgroundInfluential
Cited by
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
“, family history of alcohol use disorder [7, 8]; suicide history [9]; body mass index (BMI) [9]; benzodiazepine use [10]) and mechanistic (e.”
BackgroundSelf-citationThomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
Metadata
- Authors
- Pennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 208
- Pages
- 560-566
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2545381381
- Cited by
- 77
- References
- 32
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. https://app.cochat.ai/papers/10.1016/j.jad.2016.10.026
- The paper
- Pennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2017). Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2016.10.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.